Updated Oct 13, 7:31 PM ET
Sangamo’s Chapter 11 is on a sale-led path following the September 2, 2026 sale order Dkt. 426 approving a $111 million asset sale to PTC Therapeutics. Resolution of the remaining estate is the next substantive issue: the equity committee’s October 1 statement on professional fees Dkt. 492 argues that sale proceeds are sufficient to pay creditors in full and presses for lower administrative costs to preserve shareholder value.
Motion1:00 PM ETDkt. 471Motion of Debtor for Entry of an Order Extending Period Within Which the Debtor May Remove Actions Pursuant to 28 U.S.C. § 1452 and Rule 9027 of the Federal Rules of Bankruptcy Procedure and Granting Related Relief [Hearing scheduled for 11/2/2026 at 01:00 PM at US Bankruptcy Court, 824 Market St., 3rd Fl., Courtroom #7, Wilmington, Delaware. Objections due by 10/5/2026.] (Filed by Sangamo Therapeutics, Inc.)
in 19 daysDebt-Free Sangamo Therapeutics Files Chapter 11 With $75M Sale Bids ·
Review or edit a question about this case’s recent filings, then send it to start research.
Prepare a questionCase facts and filing dates come from court records.